Pan Tumor Rollover Study
- Conditions
- Cancer
- Registration Number
- NCT03899155
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria:<br><br> - Signed Written Informed Consent.<br><br> - Eligible to receive continued study treatment per the Parent Study, including<br> treatment beyond progression per investigator assessment in the Parent Study.<br><br> - On treatment hold in the Parent Study following long-lasting response or are<br> eligible for treatment rechallenge as defined in the Parent Study.<br><br> - WOCBP and male participants who are sexually active must agree to follow<br> instructions for method(s) of contraception as described below and included in the<br> ICF.<br><br>Exclusion Criteria:<br><br> - Participant is not eligible for study treatment per the Parent Study eligibility<br> criteria.<br><br> - Participants not receiving clinical benefit as assessed by the Investigator.<br><br> - Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness<br> which, in the opinion of the Investigator, indicates that participation in the study<br> is not in the best interest of the participant.<br><br> - Other protocol-defined Inclusion/Exclusion Criteria apply
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Adverse Events (AEs);Incidence of drug related AEs;Incidence of AEs leading to Discontinuation;Incidence of Serious Adverse Events (SAEs);Incidence of Select AEs;Incidence of Immune-Mediated AEs;Incidence of Death
- Secondary Outcome Measures
Name Time Method